{
    "clinical_study": {
        "@rank": "35072", 
        "arm_group": {
            "arm_group_label": "Treatment (Akt inhibitor MK2206)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with\n      previously treated colon or rectal cancer that has spread from the primary site to other\n      places in the body or cannot be removed by surgery. Akt inhibitor MK2206 may stop the growth\n      of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Cannot Removed by Surgery", 
        "condition": [
            "Mucinous Adenocarcinoma of the Colon", 
            "Mucinous Adenocarcinoma of the Rectum", 
            "Recurrent Colon Cancer", 
            "Recurrent Rectal Cancer", 
            "Signet Ring Adenocarcinoma of the Colon", 
            "Signet Ring Adenocarcinoma of the Rectum", 
            "Stage IIIA Colon Cancer", 
            "Stage IIIA Rectal Cancer", 
            "Stage IIIB Colon Cancer", 
            "Stage IIIB Rectal Cancer", 
            "Stage IIIC Colon Cancer", 
            "Stage IIIC Rectal Cancer", 
            "Stage IVA Colon Cancer", 
            "Stage IVA Rectal Cancer", 
            "Stage IVB Colon Cancer", 
            "Stage IVB Rectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Colonic Neoplasms", 
                "Rectal Neoplasms", 
                "Adenocarcinoma, Mucinous", 
                "Cystadenocarcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the response rate to MK-2206 (Akt inhibitor MK2206), defined as complete\n      response (CR) + partial response (PR).\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine response rate to MK-2206 in patients with phosphatase and tensin homolog\n      (PTEN) loss or phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha\n      (PIK3CA) mutation in a pretreatment biopsy from a metastatic site.\n\n      II. To determine progression-free survival (PFS) and overall survival (OS). III. To\n      determine the time to treatment failure (TTF), and duration of tumor response (DR).\n\n      IV. To determine the safety profile and tolerability of this regimen in this patient\n      population.\n\n      V. To determine effect of PTEN, v-raf murine sarcoma viral oncogene homolog B1 (BRAF),\n      PIK3CA, and v-akt murine thymoma viral oncogene homolog 1 (AKT) mutations and\n      semi-quantitative grading of PTEN expression on clinical response.\n\n      OUTLINE:\n\n      Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment\n      repeats every 28 days for up to 24 months in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed, radiologically measurable metastatic or\n             unresectable colorectal adenocarcinoma that is amenable to image-guided biopsy and\n             for which standard curative or palliative measures do not exist or are no longer\n             effective; disease in previously radiated regions may not be considered measurable\n             unless there has been demonstrated progression in the lesion\n\n          -  Patients must have failed available therapy for the treatment of advanced colorectal\n             cancer; this is defined as progressive disease during or within 6 months after\n             fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and for v-Ki-ras2 Kirsten rat\n             sarcoma viral oncogene homolog (KRAS) wild-type patients, anti-epidermal growth\n             factor receptor (EGFR) antibody (cetuximab or panitumumab) containing therapies, with\n             most recent progression by Response Evaluation Criteria in Solid Tumors (RECIST)\n             criteria; patients who had at least stable disease as best response on their prior\n             therapies (listed above) should have received at least 2 months (approximately 60\n             days) of treatment; for oxaliplatin-based therapy, failure of therapy will also\n             include patients who progressed within 12 months of adjuvant therapy and patients who\n             had oxaliplatin stopped due to toxicity\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)\n\n          -  Life expectancy of greater than 12 weeks\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin =< institution upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<\n             2.5 X institutional upper limit of normal or =< 5 X institutional upper limit of\n             normal for patients with known liver metastasis\n\n          -  Creatinine =< institution upper limit of normal OR creatinine clearance >= 60\n             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (double barrier method of birth control; abstinence) prior to study entry, for the\n             duration of study participation, and 4 months after completion of MK-2206\n             administration; should a woman become pregnant or suspect she is pregnant while she\n             or her partner is participating in this study, she should inform her treating\n             physician immediately; men treated or enrolled on this protocol must also agree to\n             use adequate contraception prior to the study, for the duration of study\n             participation, and 4 months after completion of MK-2206 administration\n\n          -  Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube\n             administration is not allowed; tablets must not be crushed or chewed\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n          -  Tumor must be wild type for the KRAS and BRAF oncogenes, and must have known PIK3CA,\n             AKT mutation status and PTEN expression status\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study; if the patient has residual\n             toxicity from prior treatment, toxicity must be =< grade 1 (or =< grade 2 for\n             peripheral neuropathy and/or alopecia)\n\n          -  Patients who are receiving or have received any other investigational agents within\n             30 days of study day 1, or who have previously received MK-2206 at any time\n\n          -  Patient has known active central nervous system (CNS) metastases and/or carcinomatous\n             meningitis; however, patients with CNS metastases who have completed a course of\n             therapy would be eligible for the study provided they are clinically stable for at\n             least 1 month prior to entry as defined as:\n\n               -  No evidence of new or enlarging CNS metastasis\n\n               -  Off steroids that are used to minimize surrounding brain edema\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to MK-2206\n\n          -  Patients receiving any medications or substances that are inhibitors or inducers of\n             cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP450 3A4) are ineligible\n\n          -  Patients with diabetes or in risk for hyperglycemia should not be excluded from\n             trials with MK-2206, but the hyperglycemia should be well controlled on oral agents\n             before the patient enters the trial\n\n          -  Cardiovascular baseline corrected QT by Fridericia's (QTcF) > 450 msec (male) or QTcF\n             > 470 msec (female) will exclude patients from entry on study\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with MK-2206\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible\n\n          -  No other prior malignancy is allowed except for the following: adequately treated\n             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated\n             stage I or II cancer from which the patient is currently in complete remission, or\n             any other cancer from which the patient has been disease free for five years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802320", 
            "org_study_id": "NCI-2013-00487", 
            "secondary_id": [
                "NCI-2013-00487", 
                "2012-0431", 
                "9340", 
                "N01CM00039", 
                "P30CA016672"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (Akt inhibitor MK2206)", 
                "description": "Given PO", 
                "intervention_name": "Akt inhibitor MK2206", 
                "intervention_type": "Drug", 
                "other_name": "MK2206"
            }, 
            {
                "arm_group_label": "Treatment (Akt inhibitor MK2206)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (Akt inhibitor MK2206)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "skopetz@mdanderson.org", 
                "last_name": "Edmund S. Kopetz", 
                "phone": "713-792-2828"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M D Anderson Cancer Center"
            }, 
            "investigator": {
                "last_name": "Edmund S. Kopetz", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Edmund Kopetz", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate (CR+PR) evaluated using RECIST version 1.1", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802320"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Samples will be analyzed using the Wilcoxon rank test. Chi-square or Fisher's exact test where appropriate will be used to determine whether high levels of marker expression correlate with PTEN status.", 
                "measure": "Validation of the enrichment biomarker signature in metastatic sites", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "Estimated using the Kaplan and Meier product limit method. Cox proportional hazards regression model will be used to identify prognostic factors for PFS.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment to time of progression or death, whichever occurs first, assessed up to 18 months"
            }, 
            {
                "description": "Estimated using the Kaplan and Meier product limit method. Cox proportional hazards regression model will be used to identify prognostic factors for OS.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "Estimated using the Kaplan and Meier product limit method. Cox proportional hazards regression model will be used to identify prognostic factors for DR.", 
                "measure": "DR", 
                "safety_issue": "No", 
                "time_frame": "From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 18 months"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}